The results of our study propose that pharmacologic treatment of the inflammatory response associated to tendinopathy would be ideally treated with pan-inflammasome inhibitors [22] or therapies targeting ASC [23,24], rather than specific NLRP3 blockers or other inhibitors targeting single inflammasomes. Here, NLRP3 is linked to disease of the tendon.